Introduction {#s1}
============

Parkinson\'s disease (PD) is the second most common neurodegenerative disorder with a rising prevalence in parallel with an aging population (Zhang et al., [@B57]; Pringsheim et al., [@B40]). Though the clinical diagnosis of PD is mainly based on cardinal motor symptoms including bradykinesia, rigidity, and rest tremor (Postuma et al., [@B39]), non-motor symptoms, such as hyposmia, depression, sleep disorders, and constipation, have attracted increasing attention because of their negative influence on the quality of life and predictive value for disease progression (Schapira et al., [@B45]). The treatment of PD remains a massive challenge because there has been no reliable tool for the early detection of PD worsening. However, the non-motor symptoms of PD can occur several years before motor manifestation progression; therefore, monitoring non-motor symptoms is considered a promising method to evaluate disease risks and promote the clinical intervention of PD at an early stage.

Rapid eye movement sleep behavior disorder (RBD) is a parasomnia characterized by loss of skeletal muscle atonia and dream-enacting behaviors associated with aggression and violence during rapid eye movement sleep (St Louis and Boeve, [@B50]). A handful of studies have demonstrated that RBD is strongly associated with PD. The prevalence of RBD is about 30% to 50% in patients with PD (Howell and Schenck, [@B21]). The occurrence of RBD in PD is associated with motor function deterioration (particularly bradykinesia worsening) (Bugalho and Viana-Baptista, [@B9]), more severe non-motor symptoms (including anxiety, depression, sleep disorders, constipation, hallucination, and orthostatic hypotension) (Neikrug et al., [@B34]; Liu et al., [@B29]), poorer cognitive function (Huang et al., [@B22]; Jozwiak et al., [@B25]), and cerebral cortex abnormalities (Barber et al., [@B5]). Thus, the presence of RBD symptoms is a risk factor and a potential marker of disease progression in PD.

Previously, many magnetic resonance imaging (MRI) studies have been conducted to investigate the functional and structural brain alterations in PD with RBD in the hope of uncovering the potential pathophysiology and characteristic changes in the brain (Bourgouin et al., [@B8]). However, due to the limited sample size and different analytical methods, the mixed results of these studies cannot be a neuroimaging biomarker in clinical practice.

Seed-based *d* mapping (SDM) is a fully validated coordinate-based meta-analytic method, which can synthesize data of neuroimaging studies using functional MRI, voxel-based morphometry (VBM), diffusion tensor imaging, or positron emission tomography (Albajes-Eizagirre et al., [@B2]). In the present study, we focused on regional volume changes of gray matter (GM) using VBM analysis. The current study aimed to calculate structural alterations in PD with RBD from published data to identify a robust neuroimaging biomarker. Therefore, we performed a coordinate-based meta-analysis of VBM studies at a whole-brain level to elucidate the prominent GM changes in PD patients with RBD.

Materials and Methods {#s2}
=====================

The present systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We prepared a prospective protocol of search strategy, inclusion criteria, data extraction, and methods of statistical analysis.

Literature Search
-----------------

We performed a systematic and comprehensive search of the PubMed, Embase, and Web of Science from inception to November 3, 2019. For the literature search in these databases, the following terms were used in combinations: ("magnetic resonance imaging" or "MRI") and ("Parkinson disease" or "Parkinson\'s disease") and ("rapid eye movement sleep behavior disorder" or "REM sleep behavior disorder" or "RBD"). Additionally, we checked the references of relevant original articles and reviews. The language of publications was restricted to English. To avoid time-lag bias, the search process was updated in June 12, 2020, but no additional study was identified.

Inclusion Criteria
------------------

We included studies in the meta-analysis that met the following criteria: (1) was published as an original article in a peer-reviewed journal; (2) demonstrated specific diagnostic criteria of PD and RBD; (3) conducted a whole-brain analysis of GM structural alterations in a stereotactic space in three-dimensional standard coordinates; (4) reported the results of VBM analysis in PD patients with and without RBD; and (5) reported significance thresholds that were either corrected for multiple comparisons or uncorrected with spatial extent thresholds. Therefore, editorials, letters, conference abstracts, reviews, book chapters, and case reports were excluded. Two authors (C.Y. and J.C.) reviewed the studies independently.

Data Extraction
---------------

We extracted peak coordinates of abnormal brain regions from all studies eligible for meta-analysis. If the manuscript used two whole-brain statistical significance levels with and without correction for multiple comparisons, we selected the uncorrected threshold and included all peaks obtained using this uncorrected threshold (Albajes-Eizagirre et al., [@B1],[@B2]). The following data were also collected: the number of patients in each group, mean age, year of education, gender ratio, disease duration, severity, and diagnostic criteria of RBD and PD. All data were evaluated independently by two authors (C.Y. and J.C.). Any disagreement about literature search, study selection, and data extraction was resolved by consensus under the guidance of the senior authors (X.B. and R.W.).

Quality Assessment
------------------

Each study was assessed for quality and completeness using a 13-item checklist as described in previous meta-analyses (Baiano et al., [@B4]; Shepherd et al., [@B48]; Du et al., [@B12]). The 13 items were divided into three categories, namely, subjects, methods for image acquisition and analysis, and results and conclusions. Each item was rated 1, 0.5, or 0 if criteria were fully met, partially met, or unfulfilled, respectively (Baiano et al., [@B4]). The checklist was designed to rate the completeness of neuroimaging studies, providing an objective indication of rigor of included studies in a meta-analysis.

Data Analysis
-------------

We conducted the voxel-wise meta-analysis of regional differences in GM volume between PD patients with and without RBD using SDM with Permutation of Subject Images (SDM-PSI version 6.21) (Albajes-Eizagirre et al., [@B1],[@B2]). The detailed coordinate-based meta-analytic process of VBM results has been described in the software tutorial (<https://www.sdmproject.com/>) and previous studies (Albajes-Eizagirre et al., [@B1]; Dahlgren et al., [@B10]). Here, we briefly summarized the SDM-PSI methods. First, the peak coordinates and *t*-statistics of GM differences between PD patients with and without RBD were extracted. To avoid potential bias, we ensured that the same statistical threshold was used in the whole brain in each study. If *t*-statistics were not presented in the publications, *z*-scores or *p*-values were converted into *t*-statistics by the SDM-PSI software. Second, the lower and upper bounds of potential effect sizes for all voxels were estimated by multiple imputations, and maps of GM alterations for each study were created by means of an anisotropic Gaussian kernel, which assigns higher effect sizes to the voxels more correlated with peak coordinates. Third, maximum likelihood techniques were used to estimate the most likely effect size and its standard error. The imputed dataset from each study was meta-analyzed using a random-effects model, and these imputed meta-analyzed datasets were combined using Rubin\'s rules. Fourth, we conducted family-wise error correction for multiple comparisons and thresholded the meta-analysis using threshold-free cluster enhancement statistics. The following SDM-PSI parameters were used: full width at half maximum (FWHM) = 20 mm, voxel size = 2 mm, imputations = 50, permutations = 1,000, threshold-free cluster enhancement family-wise error rate *P* = 0.05, cluster extent threshold = 10 voxels. Egger\'s tests and funnel plots were used to evaluate publication bias, and heterogeneity of effect sizes was assessed by *I*^2^ statistics. Besides, we performed jackknife sensitivity analyses, in which the meta-analysis was repeated after discarding one eligible study at a time to see whether the result remained statistically significant.

Results {#s3}
=======

The literature search yielded 371 publications (PubMed: 71; Embase: 200; Web of Science: 100). After screening titles and abstracts, 12 studies were reviewed in full texts. In the end, five studies were included in the current meta-analysis (Ford et al., [@B17]; Salsone et al., [@B44]; Kim et al., [@B26]; Lim et al., [@B28]; Rahayel et al., [@B41]). The process of study selection is presented in [Figure 1](#F1){ref-type="fig"}.

![Flow diagram illustrating the results of the study selection and inclusion in the current meta-analysis.](fnagi-12-00213-g0001){#F1}

Characteristics of Included Studies
-----------------------------------

There are a total of 105 PD patients with RBD and 140 without RBD. The baseline data about age, gender, education, disease duration, and disease severity were comparable between groups in each study. The diagnosis tool of PD is UK Brain Bank in four studies from 2013 to 2016 and Movement Disorder Society clinical criteria in one study in 2019. The clinical data and quality assessment scores of five included studies are presented in [Table 1](#T1){ref-type="table"}. MRI parameters are demonstrated in [Table 2](#T2){ref-type="table"}. Statistical parameters and results of VBM analyses are shown in [Table 3](#T3){ref-type="table"}. The details of quality assessment in terms of subjects, methods for image acquisitions and analysis, and results and conclusions are shown in [Table S1](#SM1){ref-type="supplementary-material"}.

###### 

Demographic and clinical data of five included studies in the present meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**            **Country**   **No. of patients**   **Age, years**   **Duration of illness,**\   **Education, years**   **Gender, men (%)**   **Severity, Hoehn and**\   **Levodopa equivalent**\   **UPDRS part 3**\   **Diagnosis of PD**   **Diagnosis of RBD**   **Quality Score**                                                                                                                        
                                                                                 **years**                                                                **Yahr stage**             **dose, mg**               **score**                                                                                                                                                                                                 
  ------------------------- ------------- --------------------- ---------------- --------------------------- ---------------------- --------------------- -------------------------- -------------------------- ------------------- --------------------- ---------------------- ------------------- ------------- --------------- --------------- ------------- ------------- --------------- -------------------------- ------
  Ford et al. ([@B17])      UK            46                    78               66.4 ± 9.9                  65.8 ± 10.9            6.5 ± 5.1             6.0 ± 4.4                  13.0 ± 3.6                 13.0 ± 4.1          36 (78.3)             48 (61.5)              2.15 ± 0.73         1.91 ± 0.56   179.2 ± 144.7   172.6 ± 128.2   26.3 ± 10.0   27.3 ± 11.9   UK Brain Bank   Mayo Sleep Questionnaire   11.5

  Salsone et al. ([@B44])   Italy         11                    11               66.6 ± 7.4                  66.9 ± 7.9             4.72 ± 4.07           4.36 ± 4.2                 NA                         NA                  8 (72.7)              8 (72.7)               1.95 ± 0.57         1.86 ± 0.59   563.6 ± 167.3   547.7 ± 155.4   21.6 ± 10.4   19.9 ± 10.3   UK Brain Bank   PSG                        13

  Kim et al. ([@B26])       Korea         9                     22               70.1 ± 6.8                  67.7 ± 8.4             1.9 ± 1.5             1.9 ± 1.4                  2.4 ± 2.5                  8.5 ± 4.8           0 (0)                 10 (45.5)              ≤ 3                 ≤ 3           NA              NA              NA            NA            UK Brain Bank   PSG                        13

  Lim et al. ([@B28])       Korea         24                    14               69.8 ± 6.4                  69.7 ± 7.2             6.2 ± 2.9             4.4 ± 3.7                  NA                         NA                  12 (50)               8 (57.1)               1.9 ± 0.4           1.6 ± 0.5     NA              NA              12.4 ± 2.5    22.4 ± 10.6   UK Brain Bank   PSG                        12

  Rahayel et al. ([@B41])   Canada        15                    15               66.7 ± 7.6                  63.1 ± 8.9             3.9 ± 2.9             3.7 ± 2.6                  14.2 ± 3.6                 15.7 ± 3.9          10 (66.7)             5 (33.3)               NA                  NA            625.2 ± 347.1   447.8 ± 171.5   24.1 ± 10.0   17.6 ± 8.5    MDS criteria    PSG                        13
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*PD, Parkinson\'s disease; RBD, rapid eye movement sleep behavior disorder; MDS, Movement Disorder Society; PSG, polysomnography. Data are presented with mean ± standard deviation*.

###### 

Magnetic resonance imaging parameters of five included studies in the present meta-analysis.

  **Study**        **Manufacturer**   **Model**   **Field strength (T)**   **Head coil**                   **FA (**°**)**   **TI (ms)**   **TE (ms)**   **TR (ms)**   **Sequence**                 **RR (mm)**
  ---------------- ------------------ ----------- ------------------------ ------------------------------- ---------------- ------------- ------------- ------------- ---------------------------- -------------------
  Ford et al.      Philip             NA          3                        NA                              NA               NA            NA            NA            MPRAGE                       1.15 × 1.15 × 1.2
  Salsone et al.   GE                 MR-750      3                        8-channel head coil             12               NA            9.2           3.7           Spoiled gradient echo        1 × 1 × 1
  Kim et al.       Phillip            Achieva     3                        Standard quadrature head coil   13               NA            2.7           7.3           Spoiled fast gradient echo   Slice thickness 1
  Lim et al.       Philip             Achieva     3                        NA                              8                NA            4.6           9.9           NA                           Slice thickness 1
  Rahayel et al.   Siemens            TrioTIM     3                        12-channel head matrix coil     9                900           2.91          2300          MPRAGE                       1 × 1 × 1

*FA, flip angle; TI, inversion time; TE, echo time; BW, bandwidth per pixel; TR, repetition time; MPRAGE, magnetization prepared rapid gradient echo; RR, reconstructed resolution*.

###### 

Statistical parameters and results of VBM analyses in five included studies.

  **Study**        **Region description**           **MNI Coordinates**   **Voxel**   **Covariate**   **Threshold**                                                         
  ---------------- -------------------------------- --------------------- ----------- --------------- --------------- ----------------------------------------------------- -------------------------------
  Ford et al.      Left parietal operculum          −62                   −7          9               407             Age, gender, intracranial volume                      *P* \< 0.001, uncorrected
                   Right superior temporal gyrus    52                    −28         13              191                                                                   
                   Left insula cortex               −32                   −15         12              146                                                                   
                   Right hippocampus                36                    −10         −14             138                                                                   
                   Left middle occipital gyrus      −39                   −91         0               131                                                                   
  Salsone et al.   Right thalamus                   −9                    −21         15              85              Age, intracranial volume                              *P* \< 0.001, uncorrected
                   Right medial temporal cortex     68                    −22         −6              176                                                                   
  Kim et al.       Right superior temporal cortex   62                    −8          8               114             Age, gender, intracranial volume                      *P* \< 0.001, uncorrected
  Lim et al.       Left lingual gyrus               −5                    −92         0               90              Age, gender, PD duration, HandY stages                *P* \< 0.001, uncorrected
                   Right cuneus                     12                    −68         6               108                                                                   
                   Left hippocampus                 −38                   −33         −5              50                                                                    
                   Left cingulate gyrus             −8                    −24         39              303                                                                   
  Rahayel et al.   Left lingual gyrus/cerebellum    −14                   −56         −9              156             Age, gender, education, MCI status, UPDRS-III score   *P* \< 0.0036, 14 comparisons

*MNI, Montreal Neurological Institute; PD, Parkinson\'s disease; MCI, mild cognitive impairment*.

Outcomes of Data Analysis
-------------------------

Our result demonstrated a significant GM volume reduction in the right superior temporal gyrus (STG) in [Figure 2](#F2){ref-type="fig"}. The cluster breakdown results show which cortical areas contribute to the corresponding cluster. We included the cortical areas with more than 10% voxels of the present cluster using 20 mm FWHM in [Table 4](#T4){ref-type="table"}. Results of Egger\'s tests (bias = −0.70, *t* = −0.39, *df* = 3, *P* = 0.699) and funnel plots in [Figure 3](#F3){ref-type="fig"} revealed no significant publication bias. There was no obvious heterogeneity of effect sizes (*I*^2^ = 2.14%) in the present meta-analysis. The main findings remained largely unchanged in the jackknife sensitivity analysis (3/5), as shown in [Table 5](#T5){ref-type="table"}.

![Decreased (red) GM volume in PD patients with RBD compared with those without RBD.](fnagi-12-00213-g0002){#F2}

###### 

Region of smaller GM volume in PD patients with RBD compared with those without RBD.

  **FWHM (mm)**   **Local peaks**                        **Cluster breakdown**                                                                                  
  --------------- -------------------------------------- ----------------------- ----- ---- -------- ------------- ----- -------------------------------------- ------------
  20              Corpus callosum                        58                      −16   4    −4.924   \~0           366   Right superior temporal gyrus, BA 22   94 (25.7%)
                  Right superior temporal gyrus, BA 48   56                      −12   8    −4.884   0.000999987         Right rolandic operculum, BA 48        69 (18.9%)
                  Right rolandic operculum, BA 48        50                      −10   10   −4.353   0.001999974         Corpus callosum                        65 (17.8%)
                  Right rolandic operculum, BA 22        62                      −14   14   −4.311   0.001999974         Right Heschl gyrus, BA 48              41 (11.2%)
                  Right superior temporal gyrus, BA 21   64                      −32   4    −3.748   0.017000020         Right superior temporal gyrus, BA 48   38 (10.4%)
                  Right superior temporal gyrus, BA 21   60                      −32   2    −3.714   0.017000020                                                
                  Right superior temporal gyrus, BA 22   58                      −26   2    −3.652   0.008000016                                                

*FWHM, full width at half maximum; BA, Brodmann area; MNI, Montreal Neurological Institute; SDM, seed-based d mapping*.

![Results of funnel plot analysis to test for publication bias.](fnagi-12-00213-g0003){#F3}

###### 

Results of jackknife sensitivity analyses.

  **Excluded study**   **Region description**                 **MNI coordinates**   **SDM (*z* Score)**   ***P***   **Voxels (*n*)**   **Cluster breakdown (Voxels, *n*, %)**         
  -------------------- -------------------------------------- --------------------- --------------------- --------- ------------------ ---------------------------------------- ----- --------------------------------------------------
  Ford et al.          NA                                     NA                    NA                    NA        NA                 NA                                       NA    NA
  Salsone et al.       Right rolandic operculum               56                    −12                   10        −4.348             0.014999986                              61    Right rolandic operculum, BA 48 (16, 26.2%)
                       Right rolandic operculum, BA 22        62                    −14                   14        −4.235             0.023000002                                    Right Heschl gyrus, BA 48 (12, 19.7%)
                       Right Heschl gyrus, BA 48              52                    −12                   6         −4.221             0.023000002                                    Right superior temporal gyrus, BA 22 (10, 16.4%)
                       Corpus callosum                        58                    −16                   4         −4.057             0.033999979                                    Right superior temporal gyrus, BA 48 (9, 14.8%)
                       Right superior temporal gyrus          64                    −16                   10        −3.903             0.044000030                                    
  Kim et al.           NA                                     NA                    NA                    NA        NA                 NA                                       NA    NA
  Lim et al.           Right superior temporal gyrus          58                    −14                   8         −5.457             0.000999987                              297   Right superior temporal gyrus, BA 22 (73, 24.6%)
                       Right rolandic operculum, BA 48        56                    −12                   12        −5.325             0.000999987                                    Right rolandic operculum, BA 48 (63, 21.2%)
                       Right rolandic operculum, BA 22        62                    −14                   14        −4.608             0.004000008                                    Corpus callosum (51, 17.2%)
                       Right superior temporal gyrus, BA 21   64                    −32                   4         −3.955             0.024999976                                    Right superior temporal gyrus, BA 48 (35, 11.8%)
                                                                                                                                                                                      Right Heschl gyrus, BA 48 (34, 11.4%)
  Rahayel et al.       Right superior temporal gyrus, BA 48   58                    −16                   8         −5.710             0.000999987                              335   Right superior temporal gyrus, BA 22 (81, 24.2%)
                       Right rolandic operculum, BA 48        56                    −12                   12        −5.490             0.000999987                                    Right rolandic operculum, BA 48 (71, 21.2%)
                       Right rolandic operculum, BA 22        62                    −14                   14        −4.834             0.000999987                                    Corpus callosum (57, 17.0%)
                       Right Heschl gyrus, BA 48              48                    −12                   8         −4.710             0.001999974                                    Right Heschl gyrus, BA 48 (40, 11.9%)
                       Right superior temporal gyrus, BA 21   64                    −32                   4         −4.066             0.018999994                                    Right superior temporal gyrus, BA 48 (37, 11.0%)

*NA, not available; MNI, Montreal Neurological Institute; SDM, seed-based d mapping; BA, Brodmann area*.

Discussion {#s4}
==========

Up to now, there has been no treatment method to slow or halt the neurodegenerative process in PD. The occurrence of RBD is a warning signal of worsening symptoms in PD patients (Romenets et al., [@B43]; Mollenhauer et al., [@B31]). The period between the onset of RBD symptoms and subtle cerebral structural changes is an ideal time window for prompt therapeutic intervention. Herein, we aimed to understand GM changes associated with RBD in PD using VBM.

To the best of our knowledge, this is the first neuroimaging meta-analysis to assess the difference of regional GM volume between PD patients with and without RBD based on VBM studies. The findings of our research can be summarized as follows: there is a significant reduction of GM volume in the right STG in PD patients with RBD compared with those without RBD.

As a newly emerging biomarker, neuroimaging has been extensively investigated for the early diagnosis and prognosis assessment in neurodegenerative disorders (Shimizu et al., [@B49]). According to human and animal studies, structural lesions in the dorsal midbrain and pons are confirmed to be responsible for idiopathic RBD (Boeve et al., [@B6]). However, the neuroanatomical basis of RBD in PD is considered different from idiopathic RBD (Dauvilliers et al., [@B11]). Thus, many studies have been performed to detect specific imaging biomarkers in PD patients before the presence of RBD using multimodal brain MRI methods (Lim et al., [@B28]; Ansari et al., [@B3]; Li et al., [@B27]), among which VBM using high-solution T1 imaging was the most widely used analysis method.

The neuroimaging studies in animal models showed that idiopathic RBD was attributed to selective lesions located in the pontine tegmentum, which was equivalent to the locus subcoeruleus in humans (Boeve et al., [@B6]). Furthermore, through VBM analysis, researchers demonstrated GM volume reduction in the anterior lobes of the right and left cerebellum, the tegmental portion of the pons, and the left parahippocampal gyrus (Hanyu et al., [@B20]) and increases of GM densities in both hippocampi (Scherfler et al., [@B46]) in patients with idiopathic RBD. In PD patients with RBD, Garcia-Lorenzo et al. ([@B18]) showed reduced signal intensity in the coeruleus/subcoeruleus complex by neuromelanin-sensitive imaging but no evident changes in GM volume. Lim et al. ([@B28]) analyzed the changes of GM volume at a whole-brain level, illustrating that RBD in PD may be related to decreased GM volume in the left posterior cingulate and hippocampus, but no structural abnormality was observed in the brainstem. Rahayel et al. ([@B41]) applied VBM and deformation-based morphometry methods to analyze the regional difference in contraction or expansion between PD patients with and without RBD but still detected no significant results in the brainstem. In summary, although brainstem abnormality is found to be associated with the promotion of idiopathic RBD from experimental and clinical perspectives (Scherfler et al., [@B46]; Hanyu et al., [@B20]), there are no apparent volume changes of GM in the brainstem in PD patients with RBD compared with those without RBD.

Previous studies have demonstrated the strong association of reduced GM volume changes in the right STG with weakened spatial processing (Ellison et al., [@B13]; Gharabaghi et al., [@B19]; Shah-Basak et al., [@B47]), narcolepsy (Joo et al., [@B24]; Weng et al., [@B54]), impaired emotion processing to support social interactions (Muller et al., [@B33]; Pan et al., [@B38]; Van de Vliet et al., [@B52]; Zhang et al., [@B55]), violent behaviors (Zhang et al., [@B56]), and some psychiatric disorders (Moreira et al., [@B32]; Zhao et al., [@B58]; Wang et al., [@B53]). Consistent with our result, sleep disorders and nocturnal violence in PD patients with RBD can be partially explained by GM volume reduction in the right STG.

GM volume reduction in the right STG was associated with motor and non-motor manifestations, accounting for the RBD-related function impairment in PD patients. The presence of RBD in PD is associated with increased frequency of depression and falling (Romenets et al., [@B43]). Significant decrease in GM density was detected in the right superior temporal pole of PD patients with depression compared with that without depression (Feldmann et al., [@B14]). According to previous studies, STG plays a substantial role in the vestibular system and is associated with spatial information processing (Janzen et al., [@B23]). Consistently, Otomune et al. found that GM volume was significantly smaller in the right STG of frequent fallers than that of non-frequent fallers (Otomune et al., [@B36]). Besides, they found a significant linear correlation between fall frequency and GM reduction in the right STG (Otomune et al., [@B36]). Together, these findings supported an essential role of the right STG in the mental and postural control of PD patients with RBD. Psychosis is the most disabling non-motor complication in PD (Ffytche et al., [@B16]). STG is involved in processing visual and auditory information (Reale et al., [@B42]). Pacchetti et al. ([@B37]) revealed that RBD increased the risk of symptomatic hallucinations and delusions in PD patients, showing the association of RBD with psychotic symptoms in PD. Additionally, there existed an inverse relationship between the severity of hallucinations and the right STG volume in early-onset schizophrenia (Matsumoto et al., [@B30]). Besides, a functional MRI study showed the association of reduced STG activity with auditory hallucinations (Orlov et al., [@B35]). Thus, our finding can partly help explain the neural substrate of association between RBD and PD psychosis. PD patients with RBD tend to develop a more rapid progression in cognition dysfunction (Fereshtehnejad et al., [@B15]). Reduced GM volume in the right STG is associated with poor ability to overcome misdirection (Tong et al., [@B51]), partly explaining its contribution to cognitive worsening in PD patients with RBD. In summary, RBD-related presentations in PD could be to some extent attributed to GM atrophy in the right STG, which can serve as a predictive tool for disease progression in PD.

The present study has some limitations that merit comment. First, polysomnography is mandatory for the diagnosis of RBD; however, the diagnosis of RBD in the research by Ford et al. was assessed by the Mayo Sleep Questionnaire, a well-validated tool for clinical screening (Ford et al., [@B17]). Second, the relatively small sample size of included studies limited the power of our meta-analysis using SDM-PSI methods. Third, VBM analysis is considered to be less sensitive in detecting regional abnormalities than cortical thickness analysis (Borghammer et al., [@B7]). Fourth, there exists heterogeneity of participants\' characteristics between studies and various methodologies in VBM studies in terms of preprocessing protocols, smoothing kernels, and statistical thresholding methods.

Conclusion {#s5}
==========

The result of our meta-analysis demonstrates that PD patient with RBD is associated with reduced GM volume of the right STG, suggesting a potential imaging biomarker for disease progression in PD. In the future, more functional neuroimaging and neurobiological studies are needed to provide further insights into how regional brain areas affect sleep disorders in PD patients.
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